Aakash Desai: NSCLC – 85% of Lung Cancers, Sales Projected to Grow from $31.7B to $56.1B by 2032

Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn about a recent paper by Charlotte B. Jago and Rachel M. Webster published in Nature:

“Nature Portfolio Reviews Drug Discovery’s latest From the Analyst’s Couch dives deep into the NSCLC market.

1. Market: NSCLC ≈ 85% of lung cancers; sales projected to grow from ~US$31.7B (2024) to ~US$56.1B by 2032.
2. Growth drivers: Expansion into adjuvant/neoadjuvant settings, rising biomarker testing, and fast-growing China/emerging markets.
3. Biology/Biomarkers: EGFR, ALK, KRAS G12C, HER2, MET, RET, etc.; ctDNA/MRD assays moving toward routine use.
4. Therapeutics: Next‑gen TKIs, ADCs, bispecifics, PROTACs; IO combos beyond PD‑1/L1 (e.g., TIGIT, LAG‑3).
5. Unmet needs: Post‑targeted and IO resistance, IO‑refractory/low PD‑L1 disease, brain mets, and equitable access to testing.
6. Trials/Regulation: Platform/adaptive designs; perioperative endpoints (pCR, EFS) under scrutiny; tighter post‑marketing requirements.
7. Access/Value: Payers demanding differentiation and outcomes data amid crowded classes.”

Title: The non-small-cell lung cancer drug market

Read the full article.

More posts featuring Aakash Desai.